PriceTargets.com logo

BioRestorative Therapies - BRTX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.11 As of 12/4/2025 04:59 PM ET
▲ +0.03 (2.78%)

This chart shows the closing price for BRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioRestorative Therapies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BRTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for BioRestorative Therapies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.11.

This chart shows the closing price for BRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in BioRestorative Therapies. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/14/2023Roth MkmReiterated RatingBuy ➝ Buy$15.00
12/7/2022Roth CapitalInitiated CoverageBuy$15.00
9/28/2022Maxim GroupInitiated CoverageBuy
12/1/2021Roth CapitalInitiated CoverageBuy$37.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.99 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

BioRestorative Therapies logo
BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.
Read More

Today's Range

Now: $1.11
Low: $1.05
High: $1.17

50 Day Range

MA: $1.41
Low: $1.04
High: $1.67

52 Week Range

Now: $1.11
Low: $0.98
High: $2.55

Volume

32,200 shs

Average Volume

189,150 shs

Market Capitalization

$9.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.18

Frequently Asked Questions

What sell-side analysts currently cover shares of BioRestorative Therapies?

The following Wall Street sell-side analysts have issued research reports on BioRestorative Therapies in the last year:
View the latest analyst ratings for BRTX.

What is the current price target for BioRestorative Therapies?

0 Wall Street analysts have set twelve-month price targets for BioRestorative Therapies in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for BioRestorative Therapies in the next year.
View the latest price targets for BRTX.

What is the current consensus analyst rating for BioRestorative Therapies?

BioRestorative Therapies currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BRTX.

What other companies compete with BioRestorative Therapies?

Other companies that are similar to BioRestorative Therapies include Cryo-Cell International, Marpai, Basel Medical Group, PharmChem and Concord Medical Services. Learn More about companies similar to BioRestorative Therapies.

How do I contact BioRestorative Therapies' investor relations team?

BioRestorative Therapies' physical mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The company's listed phone number is (631) 760-8100 and its investor relations email address is [email protected]. The official website for BioRestorative Therapies is www.biorestorative.com. Learn More about contacing BioRestorative Therapies investor relations.